Streetwise Biotech / Pharmaceuticals Articles

Biotech Files Patent Application for Nitric Oxide Delivery Device
Source: Streetwise Reports  (11/16/18)
With this development, the company advances blood/plasma transfusion technology.
More >

Daniel Carlson

Imprimis: Priming the Pumps for a Big 2019
Source: Daniel Carlson for Streetwise Reports  (11/15/18)
Daniel Carlson of Tailwinds Research profiles a biotech company he is bullish on. More >

Catalysts Approaching for U.S. Developer of Cancer Therapeutics
Source: Streetwise Reports  (11/10/18)
An H.C. Wainwright & Co. report highlighted this biotech's upcoming key events to watch. More >

Biotech Announces Preclinical Data on its Intravaginal Rings at Meeting
Source: Streetwise Reports  (11/10/18)
A ROTH Capital Partners report relayed the contents of both presented abstracts. More >

Target Price Raised on Biotech in Anticipation of Clinical Trial Presentation
Source: Streetwise Reports  (11/7/18)
An H.C. Wainwright & Co. report discussed what investors might expect to hear from the company regarding its cholesterol-lowering therapy. More >

Coverage Initiated on Developer of Targeted Gene Therapies for Cancer
Source: Streetwise Reports  (11/7/18)
A LifeSci Capital report highlighted the advantages of this biotech story's lead candidate targeting bladder cancer. More >

Selectively Targeting Alzheimer's Disease's Root Cause Is Key, Biotech Says
Source: Streetwise Reports  (11/7/18)
This firm explains how its 15 years in drug development led to and supports this conclusion. More >

Biotech’s Lead Drug Candidate Targets 'Market with Huge Potential'
Source: Streetwise Reports  (10/31/18)
A ROTH Capital Partners report outlines its reasons for initiating coverage on this epigenetic therapeutics developer, whose lead candidate is in trials in diabetes, end-stage renal disease and other indications. More >

Biotech Pinpoints Third Set of Targets for Potential Alzheimer's Treatment
Source: Streetwise Reports  (10/31/18)
With this achievement, the firm expands its potential partnering opportunities. More >

Daniel Carlson

As Anixa Starts Approaching the FDA, We Discuss Its Two Innovative Programs
Source: Daniel Carlson for Streetwise Reports  (10/27/18)
Dr. Amit Kumar, CEO of Anixa Biosciences, sits down with Daniel Carlson of Tailwinds Research to discuss the company's trials of CAR-T for solid tumors, as well as its Cchek program to distinguish between benign conditions and malignant cancer. More >

Daniel Carlson

Catasys…Future's So Bright
Source: Daniel Carlson for Streetwise Reports  (10/27/18)
Daniel Carlson of Tailwinds Research discusses a company that helps health plans solve the hidden, high-cost problem of untreated behavioral health conditions. More >

Biotech to Expand Precision Medicine Services via New Partnership
Source: Streetwise Reports  (10/24/18)
A Maxim Group report discussed the potential implications of this new collaboration in the field of personalized medicine and oncology. More >

Frederick Lacy

Hemp Producer CV Sciences' Q3 Earnings Estimates--Our View
Source: Fincom Investment Partners for Streetwise Reports  (10/24/18)
Fincom Investment Partners previews Q3 earnings estimates for a company that it believes offers the best value in cannabis/hemp. More >

Biotech Advances Monoclonal Antibody Technology and Is Awarded Gates Foundation Grant
Source: Streetwise Reports  (10/20/18)
An H.C. Wainwright & Co. report delivered the latest news regarding one of this immunotherapy firm's platforms, including the receipt of the first-ever U.S. patents for DNA-encoded monoclonal antibody technology. More >

Groundbreaking Biotech Company Takes Major Step Forward with Deal with Chinese Partner
Source: Streetwise Reports  (10/17/18)
Canada-based biotech company signs major deal with Chinese partner to advance groundbreaking technology in the skin and tendon rejuvenation space. More >

Biotech Reports Encouraging Interim Gene Therapy Data for Skin Disorder
Source: Streetwise Reports  (10/17/18)
This company's findings to date for its topical therapy candidate have encouraging implications for an orphan indication. More >

Tech Firm Launches Medical Cannabis User Data App, Lands Partnership
Source: Streetwise Reports  (10/13/18)
This "patient-care solution" is designed to help retailers make product recommendations. More >

Biotech's Antibodies Target Toxic Oligomers Implicated in Parkinson's Disease
Source: Streetwise Reports  (10/11/18)
Testing conducted as part of this Canadian company's research and development work on Parkinson's disease therapeutics has identified new potential antibody candidates. More >

This Biotech Is 'Harnessing the Microbiome's Therapeutic Potential'
Source: Streetwise Reports  (10/10/18)
A LifeSci Capital report presented a handful of key points about the firm. More >

FDA Approves Biopharma's Drug with $1.75 Billion Peak Sales Potential
Source: Streetwise Reports  (10/10/18)
An H.C. Wainwright & Co. report covered the greenlighting of two therapeutics developed by this firm, whose stock, according to the analyst, has more than fivebagger return potential. More >

Daniel Carlson

Texas Heart Takes to the CoreoGraft
Source: Daniel Carlson for Streetwise Reports  (10/10/18)
Daniel Carlson of Tailwinds Research profiles Hancock Jaffe Laboratories, which is partnering with the Texas Heart Institute to further develop an innovative graft designed for use in coronary bypass surgery. More >

Developer of Nitric Oxide Delivery Devices Rebrands to Focus on Leading Advancements
Source: Streetwise Reports  (10/9/18)
This Utah-based company rolled out an online campaign that highlights its strategic repositioning. More >

DURECT Receives Return on Schizophrenia Drug Approval
Source: Streetwise Reports  (10/3/18)
A new, once-monthly injectable treatment for schizophrenia uses patents of a small-cap, U.S.-based pharmaceutical firm. More >

Company with Cancer Radiotherapy Grows Revenue for Six Consecutive Quarters
Source: Streetwise Reports  (10/3/18)
An H.C. Wainwright & Co. report reviewed this company's Q4/18 earnings and opportunities for increasing it. More >

Partnership Greenlighted for Canadian Biotech and Chinese Health Products Firm
Source: Streetwise Reports  (9/26/18)
This regenerative medicine company moves one step closer to commercialization of its cell therapies in East Asia. More >

Showing Results: 1 to 25 of 809 Next

Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts

"PMN is looking to outlicense PMN310 after the Phase 1 study."
– André Uddin, Mackie Research Capital
"GPLY's new San Marcial resource should be in the 46–60 Moz range."
– Brien Lundin, Gold Newsletter (Jefferson Financial)
"BBI will merge with Pipestone Oil, creating Pipestone Energy."
– Tom Erik Kristiansen, Pareto Securities